Avantor (NYSE:AVTR) Price Target Lowered to $25.00 at Morgan Stanley

Avantor (NYSE:AVTR) had its price target reduced by Morgan Stanley from $27.00 to $25.00 in a research note published on Monday,Benzinga reports. They currently have an overweight rating on the stock.

Several other analysts also recently weighed in on the stock. Royal Bank of Canada lowered their price target on shares of Avantor from $33.00 to $31.00 and set an “outperform” rating for the company in a research note on Monday. UBS Group reissued a “neutral” rating and issued a $25.00 price target (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Wells Fargo & Company lowered their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday. Robert W. Baird lowered their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Finally, Raymond James reaffirmed an “outperform” rating and set a $24.00 price objective (down from $26.00) on shares of Avantor in a research note on Monday. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Avantor has an average rating of “Moderate Buy” and a consensus price target of $26.15.

Avantor Stock Performance

NYSE AVTR opened at $19.00 on Monday. Avantor has a 52-week low of $18.49 and a 52-week high of $28.00. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The company has a market capitalization of $12.93 billion, a P/E ratio of 41.30, a P/E/G ratio of 3.87 and a beta of 1.28. The company has a fifty day moving average of $21.73 and a 200-day moving average of $23.47.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period in the prior year, the firm earned $0.22 earnings per share. As a group, equities research analysts predict that Avantor will post 0.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Avantor

Several hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp increased its position in shares of Avantor by 58.0% during the third quarter. State Street Corp now owns 22,368,244 shares of the company’s stock valued at $578,666,000 after buying an additional 8,206,695 shares during the period. Janus Henderson Group PLC increased its position in shares of Avantor by 18.2% during the third quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock valued at $457,710,000 after buying an additional 2,719,615 shares during the period. Geode Capital Management LLC increased its position in shares of Avantor by 7.1% during the third quarter. Geode Capital Management LLC now owns 11,150,788 shares of the company’s stock valued at $287,791,000 after buying an additional 739,667 shares during the period. Robeco Schweiz AG increased its position in shares of Avantor by 12.5% during the fourth quarter. Robeco Schweiz AG now owns 7,612,555 shares of the company’s stock valued at $160,397,000 after buying an additional 848,814 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in shares of Avantor by 653.0% during the third quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock valued at $159,740,000 after buying an additional 5,354,678 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.